Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Risen Pharma Starts Phase 2 Trial of RP902 for Mild Cognitive Impairment
Risen Pharma Starts Phase 2 Trial of RP902 for Mild Cognitive Impairment
Read also
Verdiva Bio Preclinical Obesity Drug Data Slated for ADA 86th Sessions
Verdiva Bio to present preclinical data for oral obesity drugs VRB-103 and VRB-104 at the American Diabetes Association 86th Scientific Sessions in June.
US FDA Approves AstraZeneca's Baxfendy for Uncontrolled Hypertension Care
The US FDA approved AstraZeneca’s Baxfendy, a first-in-class aldosterone synthase inhibitor, for adults with resistant and uncontrolled hypertension.
Osteosarcoma Drug FL118 Earns FDA Orphan & Rare Pediatric Disease Status
The FDA granted rare pediatric disease and orphan drug designations to FL118, a novel camptothecin derivative for osteosarcoma developed by Roswell Park.
Sonire Therapeutics Starts US Pancreatic Cancer Focused Ultrasound Trial
Stanford University begins a clinical trial testing Sonire Therapeutics' focused ultrasound system, SUNRISE-II, for unresectable pancreatic cancer treatment.
